CN107207511A - Parp抑制剂的结晶形式 - Google Patents

Parp抑制剂的结晶形式 Download PDF

Info

Publication number
CN107207511A
CN107207511A CN201580063386.3A CN201580063386A CN107207511A CN 107207511 A CN107207511 A CN 107207511A CN 201580063386 A CN201580063386 A CN 201580063386A CN 107207511 A CN107207511 A CN 107207511A
Authority
CN
China
Prior art keywords
compound
crystalline form
depicted
further characterized
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580063386.3A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·J·比尔迈耶
拉尔夫·C·霍尔蒂万格
马丁·J·雅各布斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN107207511A publication Critical patent/CN107207511A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580063386.3A 2014-11-26 2015-11-25 Parp抑制剂的结晶形式 Pending CN107207511A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084652P 2014-11-26 2014-11-26
US62/084,652 2014-11-26
PCT/US2015/062572 WO2016086080A1 (en) 2014-11-26 2015-11-25 Crystalline forms of parp inhibitors

Publications (1)

Publication Number Publication Date
CN107207511A true CN107207511A (zh) 2017-09-26

Family

ID=54849709

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580063386.3A Pending CN107207511A (zh) 2014-11-26 2015-11-25 Parp抑制剂的结晶形式

Country Status (13)

Country Link
US (1) US10150772B2 (cg-RX-API-DMAC7.html)
EP (1) EP3224259A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017535564A (cg-RX-API-DMAC7.html)
KR (1) KR20170088894A (cg-RX-API-DMAC7.html)
CN (1) CN107207511A (cg-RX-API-DMAC7.html)
AU (1) AU2015353549A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017010588A2 (cg-RX-API-DMAC7.html)
CA (1) CA2967828A1 (cg-RX-API-DMAC7.html)
HK (1) HK1244006A1 (cg-RX-API-DMAC7.html)
IL (1) IL252162A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017006679A (cg-RX-API-DMAC7.html)
RU (1) RU2017120655A (cg-RX-API-DMAC7.html)
WO (1) WO2016086080A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482282A (zh) * 2009-08-26 2012-05-30 赛福伦公司 多环化合物的新形式

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482282A (zh) * 2009-08-26 2012-05-30 赛福伦公司 多环化合物的新形式

Also Published As

Publication number Publication date
JP2017535564A (ja) 2017-11-30
BR112017010588A2 (pt) 2018-05-15
US10150772B2 (en) 2018-12-11
MX2017006679A (es) 2018-07-06
WO2016086080A1 (en) 2016-06-02
EP3224259A1 (en) 2017-10-04
CA2967828A1 (en) 2016-06-02
IL252162A0 (en) 2017-07-31
RU2017120655A3 (cg-RX-API-DMAC7.html) 2018-12-14
KR20170088894A (ko) 2017-08-02
US20170267683A1 (en) 2017-09-21
AU2015353549A1 (en) 2017-06-01
RU2017120655A (ru) 2018-12-14
HK1244006A1 (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
KR102845326B1 (ko) Gabaa 양성 알로스테릭 조절인자의 염 및 결정 형태
TW201109334A (en) PLK inhibitor salts
US10370406B2 (en) Salts and polymorphs of SCY-078
US10604528B2 (en) Galunisertib crystalline form, preparation method thereof and use thereof
US20160354351A1 (en) Solid state forms of vemurafenib hydrochloride
CN118742544A (zh) 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式
CN117736176A (zh) 雄激素受体拮抗剂的可药用盐及其多晶型物、制备方法和用途
US10150772B2 (en) Crystalline forms of PARP inhibitors
US20240116925A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
US20220098206A1 (en) Solid state forms of oclacitinib maleate
WO2020025449A1 (en) Highly stable crystalline eltrombopag monoethanolamine salt form d1
EP2922838B1 (en) Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
AU2015247489B2 (en) Polymorphic forms and co-crystals of a c-Met inhibitor
HK40079381A (en) Novel salts and polymorphs of scy-078
HK40088128A (en) Salt of compound and pharmaceutical composition containing salt
KR20260066052A (ko) 베주클라스티닙의 결정형, 이의 제조방법 및 이의 용도
EP4114835A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
CN116063300A (zh) 一种含氮化合物的盐酸盐
HK1247196B (en) Novel salts and polymorphs of scy-078

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1244006

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170926